The drugmaker entered into an asset purchase agreement with an affiliate of New Mountain Capital, an investment firm. Under the agreement, Aceto will sell its chemicals business for $338 million in cash, plus assumption of liabilities.
In addition, Aceto intends to enter into a stalking-horse agreement for its subsidiary, Rising Pharmaceuticals.
Aceto will continue operations as it works to sell its assets.
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
